Website Search
ID 16111
Identifying the compound, Brian Druker
Description:
Interviewee: Brian Druker.
Brian Druker talks about identifying the compound.
Transcript:
He sent me a handful of compounds; I started testing them and in very short order we identified STR571 which ultimately became Gleevac as the best of the compounds they had that killed CML cells without harming normal cells. And then it was just a matter of doing all the work that it takes to get a compound out of lab into the clinic in clinical trials.
Keywords:
chronic myeloid leukemia,brian druker,gleevec,cancer drug,cml,interviewee,leukemia,compounds,clinical trials,handful,cells
This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.Related content:
- 15712. Bud and Yvonne
- Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
- SOURCE: DNAi
- 15056. Approval for Gleevec in record time, Brian Druker
- Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
- SOURCE: DNAi
- 15057. Before and after Gleevec, Brian Druker
- Brian Druker talks about the drug he developed as a turning point in the war on cancer.
- SOURCE: DNAi
- 15714. Brian Druker
- Brian Druker is a professor at Oregon Health Sciences University.
- SOURCE: DNAi
- 15082. Shutting down cancer with Gleevec, Brian Druker
- Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
- SOURCE: DNAi
- 15042. The first day of clinical trials for Gleevec, Bud and Yvonne
- Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
- SOURCE: DNAi
- 16109. Sense of urgency, Brian Druker
- Brian Druker talks about sense of urgency.
- SOURCE: DNAi
- 15054. Restoring hope with Gleevec, Brian Druker
- Brian Druker talks about how Gleevec has restored patients' hope for the future.
- SOURCE: DNAi
- 15055. Using DNA science to control CML, Brian Druker
- Brian Druker talks about how the drug he designed targets the molecular cause of CML.
- SOURCE: DNAi
- 15041. Getting the diagnosis of chronic myeloid leukemia, Bud
- Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
- SOURCE: DNAi
